Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : INCY save search
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
Published: 2023-03-27 (Crawled : 09:00) - biospace.com/
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.5%
H: 1.19%
C: 0.33%
pemazyre approval treatment
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
Published: 2023-03-24 (Crawled : 07:00) - biospace.com/
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -2.1%
H: 1.41%
C: -0.72%
update
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
Published: 2023-03-22 (Crawled : 22:00) - biospace.com/
MGNX 4 | $16.95 -3.36% -3.48% 820K
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: -6.28%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.04%
H: 0.46%
C: -1.71%
fda approval cell treatment
Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023
Published: 2023-03-21 (Crawled : 01:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.24%
H: 0.01%
C: -0.99%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.13%
H: 0.34%
C: -1.12%
trials meeting
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
Published: 2023-03-14 (Crawled : 01:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.28%
H: 0.38%
C: 0.31%
XNCR | $20.09 -1.9% -1.94% 390K
|
Health Technology
|
| O: 1.2%
H: 0.17%
C: -1.67%
MOR | $18.02 -0.22% -0.22% 640K
|
Health Technology
|
| O: -1.79%
H: 3.39%
C: 3.39%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.18%
H: 1.06%
C: 0.94%
meeting
Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline
Published: 2023-03-07 (Crawled : 12:00) - prnewswire.com
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: -1.99%
partnership sciences life pipeline
Incyte Abandons Phase III Trial for Myelofibrosis Treatment
Published: 2023-03-06 (Crawled : 16:00) - biospace.com/
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -2.27%
H: 0.58%
C: 0.07%
treatment trial
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
Published: 2023-02-28 (Crawled : 23:00) - globenewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -0.39%
H: 2.23%
C: 1.35%
MRUS | $41.3 -1.31% -1.33% 270K
|
Health Technology
|
| O: 4.04%
H: 1.21%
C: -1.92%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.04%
H: 1.31%
C: 1.06%
year financial update
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
Published: 2023-02-24 (Crawled : 13:00) - biospace.com/
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -0.3%
H: 0.14%
C: -0.53%
treatment chmp positive
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis
Published: 2023-02-16 (Crawled : 07:00) - biospace.com/
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -1.2%
H: 0.58%
C: -1.49%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -1.11%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.16%
H: 0.29%
C: -1.56%
il23 trial psoriasis
Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy
Published: 2023-02-15 (Crawled : 01:00) - prnewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -0.49%
H: 0.29%
C: -3.13%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.38%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -0.45%
H: 0.48%
C: 0.44%
ibi311 thyroid study
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
Published: 2023-02-10 (Crawled : 19:00) - biospace.com/
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -0.3%
H: 0.1%
C: -2.15%
incb5470 results study phase 2
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
Published: 2023-02-07 (Crawled : 13:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.27%
H: 0.0%
C: 0.0%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.13%
H: 1.01%
C: 0.89%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.29%
H: 0.86%
C: 0.72%
XNCR | $20.09 -1.9% -1.94% 390K
|
Health Technology
|
| O: -0.19%
H: 1.15%
C: -2.27%
MOR | $18.02 -0.22% -0.22% 640K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -0.59%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -1.02%
H: 0.29%
C: -3.04%
financial
Myelofibrosis Treatment Market to Reach $1.16 Billion, Globally, by 2031 at 4.0% CAGR: Allied Market Research
Published: 2023-02-06 (Crawled : 12:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: 2.88%
H: 1.17%
C: -2.24%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 1.64%
H: 0.24%
C: -0.17%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: 0.0%
H: 0.98%
C: 0.11%
AMRX | $5.55 0.54% 0.54% 1.1M
|
Health Technology
|
| O: 0.0%
H: 6.58%
C: 4.53%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.37%
H: 0.4%
C: -0.49%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.0%
H: 1.47%
C: 0.9%
GLTO | $0.666 -2.2% -2.25% 110K
|
Health Technology
|
| O: -1.11%
H: 3.36%
C: 1.12%
treatment research market
Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: Insight and Analysis on Over 30 Drugs and 20 Companies
Published: 2023-01-27 (Crawled : 20:00) - prnewswire.com
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
| Email alert
Add to watchlist
trials global companies market
Incyte to Present at Upcoming Investor Conference - January 24, 2023
Published: 2023-01-24 (Crawled : 15:00) - biospace.com/
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.0%
H: 0.62%
C: 0.19%
conference
Taiho Oncology Announces Publication in The New England Journal of Medicine of Pivotal Data for Futibatinib in Previously Treated Patients With Metastatic Intrahepatic Cholangiocarcinoma
Published: 2023-01-18 (Crawled : 23:00) - prnewswire.com
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.04%
H: 1.98%
C: 1.92%
publication
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -2.5%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -0.4%
H: 0.75%
C: -1.21%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -0.21%
H: 1.66%
C: 1.46%
drug tyvyt china
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
Published: 2023-01-17 (Crawled : 14:20) - biospace.com/
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -0.19%
H: 1.54%
C: 0.72%
report financial results
Hidradenitis Suppurativa Market is Expected to Grow at a Significant CAGR of 10.2% by 2032 | DelveInsight
Published: 2023-01-11 (Crawled : 16:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.45%
H: 2.09%
C: 1.71%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -0.04%
H: 0.63%
C: 0.2%
expected market
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.